Omega Therapeutics Looks To Address Disease By Tuning Genomic Regulators

Newly launched Omega Therapeutics differentiates itself from other genomic medicine companies by saying that it hopes specifically to target the structures that control gene expression and by tuning these insulated genomic domains (IGDs) come up with a new type of therapeutic that potentially can offer therapeutic benefit, maybe even a cure, in almost any disease that involves dysregulation of the genome.

Based in Cambridge, MA, and launched on 23 September after two years of incubation by Flagship Pioneering, Omega is an early-stage company that hopes to file two or three investigational new drug (IND) applications at the US Food and Drug Administration in the next 18 to 24 months. Led by former Macrolides Pharmaceuticals Inc